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iAbstract
Steroidal  saponins  have  long been  used  indirectly  in  traditional  Chinese  herbal  remedies,  such as 
“Maidong”.1 A tuber used in this medicine, Liriope muscari, yields the saponin (25R)-ruscogenin-1-yl 
β-D-xylopyranosyl-(1→3)-[β-D-glucopyranosyl-(1→2)]-β-D-fucopyranoside  from  which  the 
sapogenin  (25R)-ruscogenin  is  derived.  This  compound  displays  strong,  unique,  and  useful 
anti-inflammatory  and  immunological  properties  and  as  such  is  a  good  candidate  for  analog 
exploration.2,3 Synthesis of some analogs of this steroid are detailed here.
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1Introduction
Steroids  have  diverse  and  important  natural  roles  in  mammalian  hormonal  function,  and  share 
extensive structural similarities. Many steroids, in particular glucocorticoids such as dexamethasone or 
prednisolone  (see  structures  A  and  B),  have  potent  immunosuppressive  and  anti-inflammatory 
function.4,5 These compounds are often used to  treat  diseases of  the immune system and to target 
harmful or debilitating inflammation,  such as in the cases of Crohn's  disease,  rheumatoid arthritis, 
ulcers, cluster headaches, and a wide range of related illnesses.
One natural steroid, derived from the tubers of a plant traditionally used as a Chinese herbal remedy 
(Liriope muscari6), is (25R)-ruscogenin (see structure C). This compound shows promising and potent 
anti-inflammatory activity while avoiding the cyclooxygenase pathways that are frequently the target of 
both steroidal and non-steroidal anti-inflammatory drugs7 (COX-1 and COX-2 inhibition is associated 
with numerous adverse side effects familiar to non-steroidal and steroidal anti-inflammatory drugs 
alike). Circumvention of traditional COX-based mechanisms could potentially reduce risk of negative 
cardiovascular effects and stroke, renal failure, and irritation of the gastrointestinal tract that occur as a 
result of cyclooxygenase 1 and 2 inhibition, so it is vital that this compound is explored as a safer 
alternative to conventional drugs.
 
Structure A: Dexamethasone Structure B: Prednisolone
2Ruscogenin shows an ability to mitigate leukocyte adhesion to endothelial cells and leukocyte 
migration through inhibition of ICAM-1 (intercellular adhesion molecule 1) mRNA up-regulation and 
protein expression, and its inhibition of nuclear accumulation of NF-κB (nuclear factor kappa-B) as 
well as DNA binding activity of the latter in response to TNF-α (tumor necrosis factor alpha) 
stimulation of mammalian cells.8 It does all this, exerting significant anti-inflammatory action, without 
affecting the COX-2 pathway or affecting PGE2 presence, unlike dexamethasone (a common, potent 
glucocorticoid anti-inflammatory drug with structural similarities).9 The steroid also inhibits ROR-γ 
(retinoic acid receptor-related orphan receptor gamma), a receptor important in lymph node and Peyer's 
Patch development and in triggering a pro-inflammatory immune cell response.10 ROR-γ is also 
important to lymph node and Peyer’s patch growth, hypertrophy of which can lead to pathologic 
intestinal problems and increased susceptability to prion diseases.
In light of these effects, particularly avoidance of COX inhibition and unique inhibition of ROR-γ, 
increased study is warranted. Thus, creating a variety of analogs to this compound could be very 
important to the study and optimization of its benefits. Syntheses of some analogs, created from a 
commercially available steroidal starting material (diosgenin), are described here.
Structure C: (25R)-Ruscogenin
3Background
Efforts shown here are synthetic steps toward a ruscogenin analog saturated at C5, as well as a few 
other transformations of intermediates in the synthesis. The goal of this procedure is not to necessarily 
to attain the final molecule, but to collect samples of each intermediate for further reaction or assay. 
The rationale behind this approach is that each intermediate of this synthesis is itself a testable analog, 
so at the end of the project quite a few compounds can be assayed for biological activity. 
Scheme 1: Retrosynthetic approach to a saturated ruscogenin analog; The β-OH groups at C1 and C3 similar to that of  
ruscogenin can be acquired by opening a β-epoxide at C1 (necessary to have stereochemistry at that position predetermined, 
otherwise steric interference with the neighboring methyl group would likely result in an α-OH), and by reducing a carbonyl 
at C3. The β-epoxide from (ii) can be attained through catalytic epoxidation of the corresponding olefin in (iii), to reduce 
yield of the α-epoxide. This double bond in (iii) can be attained by selective enolate formation on the top side of the A-ring 
in ketone (iv), and concurrent oxidation. The ketone (iv) can be obtained from simple oxidation of alcohol (v), which itself 
can be furnished by catalytic hydrogenation of a common steroidal starting material called diosgenin.
The strategy shown in Scheme 1 was developed by retrosynthetic analysis of the saturated ruscogenin 
analog. A prominent feature of ruscogenin is its β-OH group at C1. So, this feature was maintained in 
the goal molecule, and a stereospecific epoxide at C1 was envisioned, which could be added from the 
corresponding olefin at C1. This double bond could be added into a saturated version of a common 
commercially-available starting material, diosgenin.
4Thus, the strategy for developing analogs to ruscogenin is to proceed according to the pathway outlined 
in Scheme 2. 
Scheme 2: a) Cat. Hydrogenation – Pd(OH)2/C + H2 in DCM/EtOH @ 55 psi, 60°C11, b) Dess-Martin Ox. – periodinane in 
DCM @ RT12,  c)  Ox.  to  Enone –  LDA and N-t-butylbenzenesulfinimidoyl  chloride  in  THF13,  d)  Cat.  Epoxidation  – 
Mo(CO)6 in DCM (THF, dioxane) @ reflux14, e) Cat. Hydrogenation – Pd(OH)2/C + H2, f) Sodium Borohydride reduction – 
NaBH4 
This strategy, with the goal of facile synthesis of ruscogenin analogs, is aimed at creating saturated 
analogs beginning with hydrogenation of the olefin. This provides a planned framework for collecting 
intermediates as testable analogs, and removes unnecessary complications that may be seen at that site 
such as migration into conjugation or secondary reactivity. Variations on the intermediates shown will 
5provide  other  useful  compounds  which  can  be  assayed  for  similar  immunological  potential.  The 
strategy for obtaining ruscogenin is based on earlier reports of synthesis15,  and has thus far proved 
successful.
Another strategy for analogs is as shown in scheme 3. 
Scheme 3: a) Dess-Martin Ox. – periodinane in DCM @ RT16, b) Methylation – MeLi in ether, -78°C → RT, 3h17, c) Oxime 
formation – NH2OH·HCl, NaOAc, reflux18,
These  products  can  be  produced  from  oxidation  of  the  starting  material,  diosgenin  1,  to  yield 
potentially  useful  analogs  in  decent  yields.  Preparation  of  the  ketone  2 proved  complicated,  as 
discussed in the following section, so this route was not explored. However, preparation of ketone  3 
proved less capricious, and as a result led to the development of scheme 4 (analogous to scheme 3), as 
shown below, to prepare an oxime that could lead the way to further functionality at the C3 site. 
6Scheme 4: a) Dess-Martin Ox. – periodinane in DCM @ RT19, b) Methylation – MeLi in ether, -78°C → RT, 3h20, c) Oxime 
formation – NH2OH·HCl, NaOAc, reflux21,
Methylation of the conjugated enone 3 was not explored, but instead performed on the ketone 5 to good 
effect, as shown below.
With the  proposed schemes,  successful  synthesis  of  many analogs  to  a  useful  steroid  with unique 
anti-inflammatory and immunological  properties  can be accomplished.  Should biological  assays  of 
these drugs prove fruitful, a grand alternative to current COX-2 inhibitors may arise as a treatment for 
many debilitating inflammatory diseases.
MeLi
7Results and Discussion
For clarity, the numbering of carbons on the starting material, diosgenin, is as shown in the following 
structure. All analogs and intermediates described hereafter follow the same numbering pattern.
(25R)-Spirostan-5-ene-3-one 2 was prepared from diosgenin 1 by means of Dess-Martin oxidation as 
shown.22 Analysis  of  the  product  by  NMR and TLC before  purification  by  flash  chromatography 
suggested decent yield, but after purification and collection of the relevant fraction it was apparent that 
there was degradation and a smaller amount than expected was obtained. Acid-catalyzed hydrolysis of 
the  spiroketal  is  the suspected cause,  due  to  the  acidic  nature  of  the silica gel  used.  In  response, 
deactivation  of  the  silica  gel  with  triethylamine  prior  to  chromatography was planned for  another 
Figure 1: Dess-Martin oxidation of diosgenin
Structure D: Diosgenin (numbered)
DM periodinane
8attempt at the reaction predicting a better yield, but this led to an unpredicted complication which is  
elucidated in the succeeding reaction discussed.
(25R)-Spirostan-4-ene-3-one  3 was  prepared  from diosgenin  1 by  means  of  another  Dess-Martin 
reaction as shown. A slightly modified procedure23 was used that predicted a better  yield,  and the 
intention of the reaction was to more efficiently generate (25R)-spirostan-5-ene-one  2 with a small 
addition of water and to prevent ketal hydrolysis during refinement by the aforementioned deactivated 
silica. Analysis  by TLC and NMR showed that the crude product was indeed steroid 2 as intended, and 
the  expected  result  of  higher  initial  yield  and  shorter  reaction  time  were  observed.  Purification, 
however, produced an unexpected outcome; the olefin at C5 had migrated to C4 in conjugation with the 
ketone at C3 (see Figure 2). This was triggered by base-catalysis brought on from deactivation with 
Figure 2: DM oxidation followed by base catalyzed olefin migration
Figure 3: Base-catalyzed double bond migration
DM periodinane Triethylamine on silica
9triethylamine24 (see Figure 3)  As a result, steroid 3 was the final product obtained, and in good yield.
Loss of the double bond at C5 is a  major structural diversion from the target molecule ruscogenin 
(Structure C), so one desired analog strategy is to maintain both its β-hydroxyl groups at C1 and C3 but 
saturate the olefin. The first strategic step in the process was to hydrogenate the bond early in order to 
avoid undesired reactivity and problems that may occur with conjugation as previously encountered. 
Synthesis  of  the  saturated  sapogenin  was  achieved  by  catalytic  hydrogenation  in  the  presence  of 
Pd(OH)2 in dichloromethane/ethanol as shown to yield (25R)-5α-spirostan-3β-ol  4 from diosgenin  1 
cleanly and in good yield (see Figure 4).
As shown in Figure 5,  the ketone  5  was derived from the saturated diosgenin analog  4.  This was 
achieved  by  Dess-Martin  periodinane  oxidation  followed  by  purification  by  silica  column 
chromatography to furnish a clean ketone with a useful carbonyl functional group at C3 which could be 
Figure 4: Catalytic hydrogenation of diosgenin
Figure 5: Dess-Martin oxidation of saturated diosgenin compound
Pd(OH)2 on C, H2
DM periodinane
10
used as a handle to make many more analogs with that site in mind (such as alkylation, amination,  
oxime formation,  etc.)  The reaction  went  to  completion,  and was clean  but  for  a  13% UV-active 
impurity that was easily removed by chromatography.
The ketone 5 was then used to produce a conjugated enone (6) with a double bond from C1 – C2, as 
shown in Figure 6, in order to functionalize the C1 site. This is an important region of the molecule to 
put a reactive handle on, given presence of a 1β-OH on ruscogenin. This enone has clear implications 
for further development of analogs to ruscogenin in the future, including the possibility of epoxidation 
followed by ring opening to install either an α or β hydroxyl group.
The reaction of 5 → 6 was performed by first deprotonating C2 with LDA to give the corresponding 
enolate,  then adding the electrophile  N-tert-butylbenzenesulfinimidoyl chloride to  oxidize,  giving a 
double bond from C1 to C2. However, both the compounds 6 and 3 were produced in a roughly 1:1 
ratio, implying a lack of regioselectivity. Starting material was also recovered after the reaction, which 
warranted investigation.  Immediate concerns were that the commercially obtained LDA was not as 
concentrated as it was claimed to be; a titration with menthol and fluorene proved that to be the case, as 
it was only about 75% of the assumed concentration. This knowledge, combined with the knowledge 
Figure 6: Olefin addition to ketone at C1
N-t-butylbenzenesulfinimidoyl chloride
LDA
11
that there was starting material left and a significant amount of 3 produced, leads to the hypothesis that 
a  limiting  amount  of  LDA could  have  led  to  enolate  exchange  between  the  three  steroidal  forms 
present,  and  thermodynamic conditions  (as  opposed  to  kinetic)  were  the  cause  of  non-selectivity 
between the two enone structures. However, a second try with appropriately adjusted LDA values gave 
a similar ratio between the two isomers (apart from amount of LDA, all conditions remained the same 
as in the procedure detailed on page 18), so it is likely that there is no apparent selectivity.
The  ketone  5 was  also  used  to  produce  two  methylated  compounds  at  C3, 
3β-methyl-(25R)-spirostan-3α-ol  and  3α-methyl-(25R)-spirostan-3β-ol,  by  alkylation  with 
methyllithium. After purification by silica column chromatography, both the β-methyl and α-methyl 
varieties were recovered, in a 10:3 ratio respectively. This ratio corresponds to that which is reported by 
Maruoka et al.17 for methylation of a similar steroid. This reaction is shown in Figure 7.
Figure 7: Methylation of ketone resulting in α-methyl and β-methyl isomers
MeLi
12
Finally, the conjugated enone 3 was used to create the corresponding oxime, for yet another analog and 
usefully functionalized steroid. Sodium acetate and hydroxylamine hydrochloride were used to produce 
a mixture of the syn and anti isomers 12 and 13, as shown in Figure 8.
Figure 8: Enone 3 oxime formation
NH2OH · HCl,
Sodium Acetate
13
Experimental
General Methods
NMR spectra (1H) were obtained with a Bruker AVANCE III 500 MHz NMR spectrometer. Chemical 
shifts  are  reported  in  ppm (δ)  with  tetramethylsilane  as  internal  standard  at  0.00  ppm.  TLC was 
performed on precoated, glass-backed silica gel plates (0.25 mm) with a 254 nm fluorescent indicator. 
These were visualized with shortwave UV light and p-anisaldehyde staining. Flash chromatography 
was performed on silica gel columns using an AnaLogix IntelliFlash 280 flash chromatography system.
14
(25R)-spirostan-5-ene-3-one 
(Keegan Leitz-I-001, NMR: KJL-I-001LC1)
1 2
To  dichloromethane  (anhydrous;  15  mL)  was  added  diosgenin  (1) (100  mg)  and  Dess-Martin 
periodinane  (181  mg).  The  mixture  was  stirred  at  room temperature  for  1.5  h.  The  reaction  was 
monitored by TLC until absence of starting material was apparent (4:1 Hexane/EtOAc). This reaction 
mixture was diluted with diethyl ether (20 mL) and quenched with 1:3 NaHCO3/Na2S2O3 (saturated 
aqueous solution). The aqueous phase was extracted with ether and the combined organic phases were 
washed with brine, then dried over Na2SO4. The organic phase was filtered and the filtrate was dried 
under  rotary  evaporation  to  yield  a  crude  white  solid.  The  crude  product  was  purified  by  flash 
chromatography on silica gel (Hexane/EtOAc 95:5 – 85:15) to yield 2 (10 mg, 10%): 1H NMR (CDCl3, 
500 MHz) δ 0.82 (d, 3H, J = 6.3 Hz), δ 0.85 (s, 3H), δ 1.01 (d, 3H, J = 7.0 Hz), δ 1.23 (s, 3H), δ 2.86 
(dd, 1H, J = 2.2 Hz), δ 3.31 (ddt, 1H, J = 3.0 Hz), δ 3.40 (t, 1H, J = 11.0 Hz), δ 3.50 (ddd, 1H, J = 11.0, 
4.0, 2.0 Hz), δ 4.46 (q, 1H, J = 7.5 Hz), δ 5.37 (dt, 1H, J = 2.0).
15
(25R)-spirostan-4-ene-3-one
(Keegan Leitz-I-002, NMR: KJL-I-002LC1)
1 3
To  dichloromethane  (anhydrous;  3  mL)  was  added  diosgenin  (1)  (100  mg)  and  Dess-Martin 
periodinane (181 mg). To dichloromethane (12 mL) was added H2O (5 μL). The wet dichloromethane 
was added via dropping funnel over 30 min, and the mixture was stirred at room temperature for 30 
min. The reaction was monitored by TLC (4:1 Hexane/EtOAc) until absence of starting material was 
apparent.  The  reaction  mixture  was  diluted  with  diethyl  ether  (20  mL)  and  quenched  with  1:3 
NaHCO3/Na2S2O3 (saturated aqueous solution). The aqueous phase was extracted with ether and the 
combined organic phases were washed with NaHCO3, then brine (x2), then dried over Na2SO4. The 
organic phase was filtered and the filtrate was dried under rotary evaporation to yield a crude white 
solid. TLC and NMR of crude material matched that of  2. The crude product was purified by flash 
chromatography on silica gel deactivated with triethylamine (Hexane/EtOAc 95:5 – 85:15) to yield 3 
(77 mg, 77%): 1H NMR (CDCl3, 500 MHz) δ 0.82 (d, 3H, J = 6.3 Hz), δ 0.86 (s, 3H), δ 1.00 (d, 3H, J = 
7.0 Hz), δ 1.23 (s, 3H), δ 3.40 (t, 1H, J = 11.0 Hz), δ 3.51 (ddd, 1H, J = 11.0, 4.0 , 2.0 Hz), δ 4.44 (q, 
1H, J = 7.5 Hz), δ 5.76 (s, 1H).
16
(25R)-5α-spirostan-3β-ol
(Keegan Leitz-I-005, NMR: KJL_I-005)
1 4
Diosgenin (1)  (300 mg) was dissolved in dichloromethane (3.5 mL) and ethanol  (6.5 mL).  To the 
solution was added palladium (II) hydroxide on carbon (20% by weight; 30.0 mg). The reaction vessel 
was placed under vacuum and subsequently flushed with hydrogen gas (x3). A balloon of hydrogen was 
placed on the flask and the reaction mixture was allowed to stir overnight. After completion, shown by 
TLC  (4:1  Hexane/EtOAc),  the  catalyst  was  filtered  off  and  the  filtrate  was  dried  under  rotary 
evaporation, yielding a crude white solid. The crude material was recrystallized from acetone to yield 4 
(284 mg, 95%): 1H NMR (CDCl3, 500 MHz) δ 0.68 (m, 1H), δ 0.79 (s, 3H), δ 0.82 (d, 3H, J = 6.3 Hz), 
δ 0.85 (s, 4H), δ 0.99 (d, 3H, J = 7.0 Hz), δ 2.01 (m, 1H), δ 3.40 (t, 1H, J = 11.0 Hz), δ 3.50 (ddd, 1H, J  
= 11.0, 4.0, 2.0 Hz), δ 3.62 (m, 1H, J = 5.0 Hz), δ 4.42 (q, 1H, J = 7.5 Hz).
17
(25R)-spirostan-3-one
(Keegan Leitz-I-011, NMR: KJL_I_011d)
4 5
Spirostanol (4) (1.5 g) and Dess-Martin periodinane (2.75 g) were dissolved in dichloromethane (35 
mL).  The reaction mixture was allowed to stir  for 2 hours at  room temperature.  After completion, 
shown by TLC (4:1 Hexane/EtOAc), the mixture was diluted with ether (20 mL) and quenched with 
1:3 NaHCO3/Na2S2O3. The aqueous phase was extracted with ether and the combined organic phases 
were washed with H2O and brine before being dried over Na2SO4. The dried organic layer was filtered 
and subjected to rotary evaporation.  The crude was purified by flash chromatography on silica gel 
(Hexane:EtOAc 95:5 – 85:15) to furnish 5 (1.024 g, 68%): 1H NMR (CDCl3, 500 MHz) δ 0.82 (d, 3H, J 
= 6.0 Hz), δ 0.82 (s, 3H), δ 1.00 (d, 3H, J = 6.5 Hz), δ 1.06 (s, 3H), δ 3.40 (t, 1H, J = 11.0 Hz), δ 3.50 
(ddd, 1H, J = 11.0, 4.0, 2.0 Hz), δ 4.43 (q, 1H, J = 7.0 Hz).
DM periodinane
18
(25R)-spirostan-1-ene-3-one
(Keegan Leitz-I-013, NMR: KJL_I_013p1)
5 6
All flasks and syringes were oven dried and/or rigorously dried by heat/vacuum cycles before use. 
Lithium diisopropylamide (0.9 mL, 1.5M in THF) was cooled to -78°C in a dry ice bath. Spirostanone 
(5)  (500  mg)  was  dissolved  in  dry  THF  (3  mL)  and  added  to  the  LDA.  N-tert-butyl- 
benzenesulfinimidoyl chloride (432 mg) was dissolved in dry THF (3 mL) and added to the reaction 
mixture. The reaction mixture was allowed to stir 1 h, then was quenched with NaHCO3 (sat. aq.). The 
aqueous phase was extracted with ethyl acetate and the combined organic phases were washed with 
H2O and brine. The organic layer was dried over Na2SO4, filtered, and subjected to rotary evaporation. 
The crude was purified by flash column chromatography on silica (dichloromethane:EtOAc 97:3 – 
93:7) to furnish (25R)-spirostan-1-ene-3-one (6) (117 mg, 23%): 1H NMR (CDCl3, 500 MHz) δ 0.82 (d, 
3H, J = 6.0 Hz), δ 0.84 (s, 3H), δ 1.01 (d, 3H, J = 7.0 Hz), δ 1.06 (s, 3H), δ 2.25 (ddd, 1H, J = 18.0, 4.0  
Hz), δ 2.40 (dd, 1H, J = 18.0, 15.0 Hz), δ 3.40 (t, 1H, J = 11.0 Hz), δ 3.50 (ddd, 1H, J = 11.0, 4.0 , 2.0 
Hz),  δ  4.44 (q,  1H,  J  = 7.0 Hz),  δ  5.88 (d,  1H, J  = 10.0 Hz),  δ  7.16 (d,  1H,  J  = 10.0 Hz);  and 
(25R)-spirostan-4-ene-3-one (3) (115 mg, 23%):  1H NMR (CDCl3, 500 MHz) δ 0.82 (d, 3H, J = 6.3 
Hz), δ 0.86 (s, 3H), δ 1.00 (d, 3H, J = 7.0 Hz), δ 1.23 (s, 3H), δ 3.40 (t, 1H, J = 11.0 Hz), δ 3.51 (ddd, 
1H, J = 11.0, 4.0, 2.0 Hz), δ 4.44 (q, 1H, J = 7.5 Hz), δ 5.76 (s, 1H).
N-t-butylbenzenesulfinimidoyl chloride
LDA
19
3β-methyl-(25R)-spirostan-3α-ol and 3α-methyl-(25R)-spirostan-3β-ol
(Keegan Leitz-I-010, NMR: KJL_I_010-iso1 and KJL_I_010-iso2, respectively)
10
5
11
All flasks and syringes were oven dried and/or rigorously dried by heat/vacuum cycles before use. 
Spirostanone (5) (100 mg) was dissolved in anhydrous ether (1 mL) and anhydrous dichloromethane 
(0.7 mL). The reaction vessel was cooled to  -78°C in a dry ice bath. Methyllithium (0.2 mL, 1.6 M in 
ether) was added dropwise to the solution. The reaction was quenched after 1 h with H2O (3 mL). The 
aqueous phase was extracted with ether and the combined organic phases were washed with brine 
before drying by Na2SO4. The organic layer was filtered, dried by rotary evaporation, and subjected to 
flash  chromatography  on  silica  (Hexane:EtOAc  95:5  –  85:15)  to  furnish 
3β-methyl-(25R)-spirostan-3α-ol (11) (56 mg, 55%): 1H NMR (CDCl3, 500 MHz) δ 0.79 (s, 6H), δ 0.82 
(d, 3H, J = 6.0 Hz), δ 0.99 (d, 3H, J = 7.0 Hz), δ 1.23 (s, 3H), δ 3.41 (t, 1H, J = 11.0 Hz), δ 3.50 (ddd,  
1H, J = 11.0, 4.0, 2.0 Hz), δ 4.42 (q, 1H, J = 7.0 Hz); and 3α-methyl-(25R)-spirostan-3β-ol (10) (17 mg, 
16%): 1H NMR (CDCl3, 500 MHz) δ 0.79 (s, 3H), δ 0.82 (d, 3H, J = 6.0 Hz), δ 0.85 (s, 3H), δ 0.99 (d,  
3H, J = 7.0 Hz), δ 1.27 (s, 3H), δ 3.41 (t, 1H, J = 11.0 Hz), δ 3.50 (ddd, 1H, J = 11.0, 4.0, 2.0 Hz), δ  
4.42 (q, 1H, J = 7.0 Hz).
MeLi
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(25R)-spirostan-4-ene-3-one oxime
(Keegan Leitz-I-006, NMR: KJL_I-006a)
3 12 + 13
Spirostan-4-ene-3-one (3) (50 mg) was dissolved in methanol (2 mL) and brought to reflux. Sodium 
acetate (75 mg) and hydroxylamine hydrochloride (50 mg) were dissolved in H2O (1 mL) and added  to 
the refluxing solution of 3. The reaction mixture was refluxed for 4 h, then allowed to cool. This was 
then  filtered,  washed  with  30% aqueous  methanol,  and  dried.  The  crude  was  recrystallized  from 
methanol to yield the oximes as an 85:15 mixture of isomers  12  and  13 (35 mg, 67%): 1H NMR 
(CDCl3, 500 MHz) δ 0.82 (d, 3H, J = 6.0 Hz), δ 0.84 (s, 3H), δ 1.00 (d, 3H, J = 7.0 Hz), δ 1.10 (s,  
2.6H), δ 1.15 (s, 0.5H), δ 3.07 (ddd, 0.8H, J = 17.0, 5.0, 3.0 Hz), δ 3.40 (t, 1H, J = 11.0 Hz), δ 3.50  
(ddd, 1H, J = 11.0, 4.0, 2.0 Hz), δ 4.43 (q, 1H, J = 7.0 Hz), δ 5.79 (s, 0.8H), δ 6.50 (s, 0.2H).
NH2OH · HCl,
Sodium Acetate
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Spectral Data
Figure 1: 1H NMR Spectrum of diosgenin (1)
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Figure 2: 1H NMR Spectrum of (25R)-spirostan-5-ene-3-one (2)
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Figure 3: 1H NMR Spectrum of (25R)-spirostan-4-ene-3-one (3)
24
Figure 4: 1H NMR Spectrum of (25R)-5α-spirostan-3β-ol (4)
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Figure 5: 1H NMR Spectrum of (25R)-spirostan-3-one (5)
26
Figure 6: 1H NMR Spectrum of (25R)-spirostan-1-ene-3-one (6)
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Figure 7: 1H NMR Spectrum of 3β-methyl-(25R)-spirostan-3α-ol (11)
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Figure 8: 1H NMR Spectrum of 3α-methyl-(25R)-spirostan-3β-ol (10)
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Figure 9: 1H NMR Spectrum of (25R)-spirostan-4-ene-3-one oxime mixture (12+13)
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